The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Regulation of mTORC1 and mTORC2 Complex Assembly by Phosphatidic Acid: Competition with Rapamycin
Open accessAbstract
mTOR, the mammalian target of rapamycin, is a critical node for control of cell growth and survival and has widely been implicated in cancer survival signals. mTOR exists in two complexes: mTORC1 and mTORC2. Phospholipase D (PLD) and its metabolite phosphatidic acid (PA) have been implicated in the regulation of mTOR; however, their role has been controversial. We report here that suppression of PLD prevents phosphorylation of the mTORC1 substrate S6 kinase (S6K) at Thr389 and the mTORC2 substrate Akt at Ser473. Suppression of PLD also blocked insulin-stimulated Akt phosphorylation at Ser473 and the mTORC2-dependent phosphorylation of PRAS40. Importantly, PA was required for the association of mTOR with Raptor to form mTORC1 and that of mTOR with Rictor to form mTORC2. The effect of PA was competitive with rapamycin-with much higher concentrations of rapamycin needed to compete with the PA-mTORC2 interaction than with PA-mTORC1. Suppressing PA production substantially increased the sensitivity of mTORC2 to rapamycin. Data provided here demonstrate a PA requirement for the stabilization of both mTORC1 and mTORC2 complexes and reveal a mechanism for the inhibitory effect of rapamycin on mTOR. This study also suggests that by suppressing PLD activity, mTORC2 could be targeted therapeutically with rapamycin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
Kim, D.-H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 2,986
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
mTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322
PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase
Sancak, Y., Thoreen, C. C., Peterson, T. R., Lindquist, R. A., Kang, S. A., Spooner, E., Carr, S. A., & Sabatini, D. M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.03.003 · Cited by 1,236
Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40
Haar, E. V., Lee, S.-I., Bandhakavi, S., Griffin, T. J., & Kim, D.-H. (2007) · Nature Cell Biology · doi:10.1038/ncb1547 · Cited by 1,190
Phosphatidic Acid-Mediated Mitogenic Activation of mTOR Signaling
Fang, Y., Vilella-Bach, M., Bachmann, R., Flanigan, A., & Chen, J. (2001) · Science · doi:10.1126/science.1066015 · Cited by 1,055
Cited by
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
Laplante, M., & Sabatini, D. M. (2009) · Journal of Cell Science · doi:10.1242/jcs.051011 · Cited by 2,170
Reprogramming of fatty acid metabolism in cancer
Koundouros, N., & Poulogiannis, G. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0650-z · Cited by 1,614
Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks
Magnuson, B., Ekim, B., & Fingar, D. C. (2012) · Biochemical Journal · doi:10.1042/bj20110892 · Cited by 1,015
Regulation and metabolic functions of mTORC1 and mTORC2
Szwed, A., Kim, E., & Jacinto, E. (2021) · Physiological Reviews · doi:10.1152/physrev.00026.2020 · Cited by 813
mTOR complex 2 signaling and functions
Oh, W. J., & Jacinto, E. (2011) · Cell Cycle · doi:10.4161/cc.10.14.16586 · Cited by 562
Mammalian Target of Rapamycin (mTOR): Conducting the Cellular Signaling Symphony
Foster, K. G., & Fingar, D. C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.r109.094003 · Cited by 534
TOR Signaling and Nutrient Sensing
Dobrenel, T., Caldana, C., Hanson, J., Robaglia, C., Vincentz, M., Veit, B., & Meyer, C. (2016) · Annual Review of Plant Biology · doi:10.1146/annurev-arplant-043014-114648 · Cited by 446
Phospholipase D: Enzymology, Functionality, and Chemical Modulation
Selvy, P. E., Lavieri, R. R., Lindsley, C. W., & Brown, H. A. (2011) · Chemical Reviews · doi:10.1021/cr200296t · Cited by 389
MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice
Zhang, D., Contu, R., Latronico, M. V. G., Zhang, J. L., Rizzi, R., Catalucci, D., Miyamoto, S., Huang, K., Ceci, M., Gu, Y., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43008 · Cited by 337
Yu, K., Toral-Barza, L., Shi, C., Zhang, W.-G., Lucas, J., Shor, B., Kim, J., Verheijen, J., Curran, K., Malwitz, D. J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0299 · Cited by 330
Bodemann, B. O., Orvedahl, A., Cheng, T., Ram, R. R., Ou, Y.-H., Formstecher, E., Maiti, M., Hazelett, C. C., Wauson, E. M., Balakireva, M., et al. (2011) · Cell · doi:10.1016/j.cell.2010.12.018 · Cited by 317
The role of mammalian target of rapamycin (mTOR) in insulin signaling
Yoon, M.-S. (2017) · Nutrients · doi:10.3390/nu9111176 · Cited by 300
“Although PA maintains the stability of mTORC1 and mTORC2 at the steady state [27], PLD1-generated PA displaces DEPTOR from mTORC1 [28].”
BackgroundPhospholipase signalling networks in cancer
Park, J. B., Lee, C. S., Jang, J.-H., Ghim, J., Kim, Y.-J., You, S., Hwang, D., Suh, P.-G., & Ryu, S. H. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3379 · Cited by 276
Phospholipase D Signaling Pathways and Phosphatidic Acid as Therapeutic Targets in Cancer
Bruntz, R. C., Lindsley, C. W., & Brown, H. A. (2014) · Pharmacological Reviews · doi:10.1124/pr.114.009217 · Cited by 276
Foster, D. A., Yellen, P., Xu, L., & Saqcena, M. (2010) · Genes & Cancer · doi:10.1177/1947601910392989 · Cited by 275
Self-citationJiang, F., Waterfield, N. R., Yang, J., Yang, G., & Jin, Q. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.04.010 · Cited by 270
Tti1 and Tel2 Are Critical Factors in Mammalian Target of Rapamycin Complex Assembly
Kaizuka, T., Hara, T., Oshiro, N., Kikkawa, U., Yonezawa, K., Takehana, K., Iemura, S.-I., Natsume, T., & Mizushima, N. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.121699 · Cited by 255
Diz-Muñoz, A., Thurley, K., Chintamen, S., Altschuler, S. J., Wu, L. F., Fletcher, D. A., & Weiner, O. D. (2016) · PLOS Biology · doi:10.1371/journal.pbio.1002474 · Cited by 187
You, J.-S., Lincoln, H. C., Kim, C.-R., Frey, J. W., Goodman, C. A., Zhong, X.-P., & Hornberger, T. A. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.531392 · Cited by 163
Intersection of mTOR and STAT signaling in immunity
Saleiro, D., & Platanias, L. C. (2015) · Trends in Immunology · doi:10.1016/j.it.2014.10.006 · Cited by 142
Regulation of TOR by small GTPases
Durán, R. V., & Hall, M. N. (2012) · The EMBO Reports · doi:10.1038/embor.2011.257 · Cited by 102
Ghobrial, I. M., Weller, E., Vij, R., Munshi, N. C., Banwait, R., Bagshaw, M., Schlossman, R., Leduc, R., Chuma, S., Kunsman, J., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70028-6 · Cited by 95
TOR kinase complexes and cell migration
Liu, L., & Parent, C. A. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201102090 · Cited by 87
Glutamine as an Essential Amino Acid for KRas-Driven Cancer Cells
Bernfeld, E., & Foster, D. A. (2019) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2019.03.003 · Cited by 85
Self-citationNorambuena, A., Wallrabe, H., McMahon, L., Silva, A., Swanson, E., Khan, S. S., Baerthlein, D., Kodis, E., Oddo, S., Mandell, J. W., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.08.015 · Cited by 79
“that Gas regulates PKA through its control of adenylate cyclase [32], that RalA is required for activation of phospholipase D, which generates the mTOR activator, phosphatidic acid [33], and that Rac1 targets both mTORC1 and mTORC2 to membranes by directly binding mTOR [14].”
Phosphatidic acid regulation of phosphatidylinositol 4-phosphate 5-kinases
Cockcroft, S. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2009.03.007 · Cited by 64
Regulation of Membrane Turnover by Phosphatidic Acid: Cellular Functions and Disease Implications
Thakur, R., Naik, A., Panda, A., & Raghu, P. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00083 · Cited by 58
Rheb G-Proteins and the Activation of mTORC1
(2010) · The Enzymes · doi:10.1016/s1874-6047(10)27003-8 · Cited by 41
“Furthermore, it is shown that phosphatidic acid, the product of PLase D, is required for the formation of mTORC1 and mTORC2 complexes [69].”
BackgroundKou, P., Wei, S., & Xiong, F. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867325666180330094434 · Cited by 6
Metadata
- Authors
- Toschi, A., Lee, E., Xu, L., Garcia, A., Gadir, N., & Foster, D. A.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2009-03-01
- Volume
- 29
- Issue
- 6
- Pages
- 1411-1420
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2114956843
- Cited by
- 333
- References
- 40
- FWCI
- 8.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.